[1] |
Hughes A, Yong ASM. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission. Front Immunol, 2017, 8: 469. doi: 10.3389/fimmu.2017.00469.
doi: 10.3389/fimmu.2017.00469
pmid: 28484463
|
[2] |
中华医学会血液学分会.慢性髓性白血病中国诊断与治疗指南(2020年版). 中华血液学杂志, 2020, 41 (5): 353-364. doi: 10.3760/cma.j.issn.0253-2727.2020.05.001.
doi: 10.3760/cma.j.issn.0253-2727.2020.05.001
|
[3] |
Granatowicz A, Piatek CI, Moschiano E, et al. An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians. Korean J Fam Med, 2015, 36(5):197-202. doi: 10.4082/kjfm.2015.36.5.197.
doi: 10.4082/kjfm.2015.36.5.197
pmid: 26435808
|
[4] |
Glaziou P, Sismanidis C, Floyd K, et al. Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med, 2014, 5(2): a017798. doi: 10.1101/cshperspect.a017798.
doi: 10.1101/cshperspect.a017798
|
[5] |
董航, 杜映荣. 糖尿病与肺结核共病的临床研究进展. 结核与肺部疾病杂志, 2022, 3(1): 65-69. doi: 10.19983/j.issn.2096-8493.20210121.
doi: 10.19983/j.issn.2096-8493.20210121
|
[6] |
董晓伟, 刘玉琴, 卢水华. 结核分枝杆菌潜伏感染的治疗: 利大于弊还是弊大于利. 中国实用内科杂志, 2019, 39(5): 443-446. doi: 10.19538/j.nk2019050112.
doi: 10.19538/j.nk2019050112
|
[7] |
李虹艾, 李帮涛, 刘鹂, 等. 国内白血病合并结核病临床病例分析. 中国感染与化疗杂志, 2019, 19(3): 243-247. doi: 10.16718/j.1009-7708.2019.03.003.
doi: 10.16718/j.1009-7708.2019.03.003
|
[8] |
Al-Anazi KA, Al-Jasser AM, Evans DA. Infections caused by mycobacterium tuberculosis in patients with hematological disorders and in recipients of hematopoietic stem cell transplant, a twelve year retrospective study. Ann Clin Microbiol Antimicrob, 2007, 6: 16. doi: 10.1186/1476-0711-6-16.
doi: 10.1186/1476-0711-6-16
URL
|
[9] |
Chen CY, Sheng WH, Cheng A, et al. Clinical characteristics and outcomes of Mycobacterium tuberculosis disease in adult patients with hematological malignancies. BMC Infect Dis, 2011, 11: 324. doi: 10.1186/1471-2334-11-324.
doi: 10.1186/1471-2334-11-324
URL
|
[10] |
Shu CC, Liao KM, Chen YC, et al. The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. Sci Rep, 2019, 9(1): 11901. doi: 10.1038/s41598-019-48395-8.
doi: 10.1038/s41598-019-48395-8
URL
|
[11] |
Liu CJ, Hong YC, Teng CJ, et al. Risk and impact of tuberculosis in patients with chronic myeloid leukemia: a nationwide population-based study in Taiwan. Int J Cancer, 2015, 136(8):1881-1887. doi: 10.1002/ijc.29201.
doi: 10.1002/ijc.29201
URL
|
[12] |
中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43 (11): 918-946. doi: 10.3760/cma.j.cn112147-20200508-00570.
doi: 10.3760/cma.j.cn112147-20200508-00570
|
[13] |
中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版). 中华结核和呼吸杂志, 2019, 42 (5): 343-356. doi: 10.3760/cma.j.issn.1001-0939.2019.05.007.
doi: 10.3760/cma.j.issn.1001-0939.2019.05.007
|
[14] |
Yang TW, Park HO, Jang HN, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study. Medicine (Baltimore), 2017, 96(28): e7482. doi: 10.1097/MD.0000000000007482.
doi: 10.1097/MD.0000000000007482
|
[15] |
Cao L, Greenblatt DJ, Kwara A. Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes. Drug Metab Dispos, 2017, 45(9):1035-1043. doi: 10.1124/dmd.117.076034.
doi: 10.1124/dmd.117.076034
URL
|
[16] |
Climent N, Plana M. Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection. Front Pharmacol, 2019, 10:1232. doi: 10.3389/fphar.2019.01232.
doi: 10.3389/fphar.2019.01232
pmid: 31680987
|
[17] |
Ghadyalpatil N, Prabhash K, Menon H, et al.Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib J Clin Oncol, 2010,28(15 suppl): 6594. doi: 10.1200/jco.2010.28.15_suppl.6594.
doi: 10.1200/jco.2010.28.15_suppl.6594
|
[18] |
Bhuiyan TM, Rahman MM, Hoque MN, et al. Peritoneal Tuberculosis in a Patient with Chronic Myeloid Leukemia and Diabetes Mellitus: A Diagnostic Dilemma. BIRDEM Medical Journal, 2013, 3(2): 281-297. doi: 10.3329/birdem.v3i2.17217.
doi: 10.3329/birdem.v3i2.17217
|
[19] |
Bhatnagar V, Adelakun A, Kendall T, et al. Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis. Arch Iran Med, 2015, 18(1):65-68.
doi: 0151801/AIM.0015
pmid: 25556390
|
[20] |
Kim DJ, Jeong S, Kong SG, et al. First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia. Blood Res, 2019, 54(2):151-153. doi: 10.5045/br.2019.54.2.151.
doi: 10.5045/br.2019.54.2.151
URL
|